Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

Forty-nine protease inhibitor (PI)-experienced but amprenavir (APV)-naïve patients experiencing virological failure were treated with ritonavir (RTV) (100 mg twice a day [b.i.d.]) plus APV (600 mg b.i.d.). Patients responded to therapy with a median viral load decrease of −1.32 log(10) by week 12. T...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Marcelin, Anne-Geneviève, Lamotte, Claire, Delaugerre, Constance, Ktorza, Nadine, Ait Mohand, Hocine, Cacace, Raquel, Bonmarchand, Manuela, Wirden, Marc, Simon, Anne, Bossi, Philippe, Bricaire, François, Costagliola, Dominique, Katlama, Christine, Peytavin, Gilles, Calvez, Vincent
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2003
Assuntos:	Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC151735/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12543665/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.2.594-600.2003
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!